Infinity, AbbVie deal

Infinity said AbbVie ended the companies’ 2014 deal to co-develop and co-commercialize duvelisib

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE